Drug intelligence / Profile preview

AD-227A

Development stage: Phase 3
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-227A is a small molecule drug developed by Addpharma for the treatment of essential hypertension. It is being studied both as a single agent and in combination with another investigational agent, AD-227B. The primary focus of current clinical trials is to evaluate its efficacy, safety, and pharmacokinetic characteristics in patients with essential hypertension. As of 2025, it has reached Phase 3 clinical development for this indication[7][6][4]. The precise mechanism of action and molecular target(s) have not been publicly disclosed.

Beyond the preview

Go deeper on AD-227A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-227A.

Explore the full profile